Browsing Tag
ANCA-associated vasculitis
2 posts
Mirador Therapeutics licenses long-acting KP-301 antibody from Kira Pharmaceuticals to enter ANCA-associated vasculitis
Mirador licenses long-acting anti-C5a antibody KP-301 from Kira, with Phase 1 planned in 2026 and an AAV Phase 2 study targeted for 2027.
Why complement pathway competition in renal disease is intensifying around oral C5aR therapies
InflaRx N.V. is expanding izicopan across renal diseases as complement therapy competition intensifies. Discover what this means for nephrology markets.